Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPKAPK5 | Q8IW41 | 2/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.40 |
| ▸ | KDM1A | O60341 | 2/20 | 0.40 |
| ▸ | MT-CO2 | P00403 | 2/20 | 0.40 |
| ▸ | ALDH2 | P05091 | 8/20 | 0.38 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.37 |
| ▸ | SYK | P43405 | 1/20 | 0.36 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.36 |
| ▸ | MAPK8 | P45983 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13922255 | 0.93 | HDAC6 (0.44) | MAPKAPK5HDAC1KDM1AALDH2RXFP1 | |
| SCHEMBL12618789 | 0.92 | SYK (0.43) | MAPKAPK5MT-CO2ROCK2SYKRXFP1 | |
| SCHEMBL13922253 | 0.91 | BTK (0.45) | MAPKAPK5 | |
| SCHEMBL12618809 | 0.91 | KDM1A (0.42) | MAPKAPK5HDAC1KDM1AALDH2ROCK2 | |
| SCHEMBL12618788 | 0.90 | MAPT (0.45) | MAPKAPK5HDAC1ALDH2ROCK2 | |
| SCHEMBL12618901 | 0.90 | MAPKAPK5 (0.41) | MAPKAPK5HDAC1KDM1AALDH2SYK | |
| SCHEMBL12618762 | 0.88 | ALDH1A1 (0.44) | MAPKAPK5ROCK2 | |
| SCHEMBL1674304 | 0.88 | MAPKAPK5 (0.57) | MAPKAPK5HDAC1KDM1AALDH2MAPK8 | |
| SCHEMBL12618857 | 0.86 | MAPKAPK5 (0.45) | MAPKAPK5SYK | |
| SCHEMBL13922270 | 0.85 | MAPKAPK5 (0.46) | MAPKAPK5ROCK2SYKMAPK8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7951818-B2 | Imidazolopyridine compounds useful for the treatment of degenerative and inflammatory diseases | GALAPAGOS NV (BE) | 2011-05-31 | — | — | US | disclosed |
| US-7951818-B2 | Imidazolopyridine compounds useful for the treatment of degenerative and inflammatory diseases | GALAPAGOS NV (BE) | 2011-05-31 | — | — | US | disclosed |
| US-20090048245-A1 | Imidazolopyridine compounds useful for the treatment of degenerative and inflammatory diseases | GALAPAGOS NV (BE) | 2009-02-19 | — | — | US | disclosed |
| US-20090048245-A1 | Imidazolopyridine compounds useful for the treatment of degenerative and inflammatory diseases | GALAPAGOS NV (BE) | 2009-02-19 | — | — | US | disclosed |
| WO-2008065199-A1 | IMIDAZOLOPYRIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | GALAPAGOS N.V. (BE) | 2008-06-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048245-A1 | Imidazolopyridine compounds useful for the treatment of degenerative and inflammatory diseases | COL2A1, MMP1, COL1A1 | MAPKAPK5 19/4885HDAC1 1487/4885KDM1A 2804/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.